Table 1.

Additional miRNAs reported to be differentially expressed in postmortem brain tissue, cerebrospinal fluid (CSF), peripheral blood mononuclear cells (PBMCs), plasma, or serum of Alzheimer’s disease (AD) patients.

miRNA	Subjects	Material	Results	Reference
miR-125b	10 AD patients, 5 controls	frontal cortex	increased in AD patients, correlating with increased tau phosphorylation	Banzhaf-Strathmann, Benito et al., 2014 [34]
miR-132-3p	hippocampi from 41 AD patients and 23 controls; prefrontal cortices from 49 individuals at Braak stage I-VI and 7 controls	hippocampus, prefrontal cortex	decreased in AD	Lau, Bossers et al., 2013 [73]
miR-107	19 individuals, Braak stage 0-VI	temporal cortex (Brodmann area 21/22)	decreasing with increased Braak stage	Nelson and Wang, 2010 [74]
miR-212 miR-132	brains from 11 AD, 7 “high pathology controls”, 9 controls; plasma from 16 AD patients, 16 AD-MCI subjects, and 31 controls	brains and neurally derived plasma exosomes	decreased in AD brains and neurally-derived plasma exosomes	Cha, Mengel et al., 2019 [75]
12 miR signature	48 AD patients, 22 controls	PBMC	separated AD patients from controls with 93.3% accuracy	Leidinger and Backes et al., 2013 [26]
miR-146a	30 AD patients, 28 controls	Plasma	no correlation with AD diagnosis, but correlation with age and lower MMSE scores	Maffioletti, Milanesi et al., 2020 [76]
miR-501-3p	27 AD patients, 18 controls	Serum	decreased in AD compared to age-matched controls; lower expression correlated with lower MMSE scores	Hara, Kikuchi et al., 2017 [30]
miR-125b	22 AD patients, 18 subjects with non-inflammatory, and 8 subjects with inflammatory neurological conditions; 10 frontotemporal dementia patients	Serum	decreased in AD compared to non-inflammatory neurological conditions	Galimberti and Villa et al., 2014 [27]